SURI

SURI, an actively managed fund, utilizes a multi-asset strategy by investing in equity and fixed income securities of companies in the biotech, pharmaceuticals, healthcare technology, and life science tools and services industries. These securities focus on common and preferred stocks, convertible bonds, structured notes, corporate notes and bonds, and ETFs. There are no restrictions as to the currency, issuer capitalization, or country for equities, and no restriction as to debt credit quality, maturity, structure, or issuer type for debt securities. The fund's management team identifies companies that present attractive investment opportunities by evaluating the scientific proposition of the issuer, the probability that the science will lead to a product or treatment, and projected profits from each successful product or treatment. Small- and mid-caps are typically included in the fund. SURI may invest up to 20% of the fund in derivatives to leverage exposure and partially hedge against market declines. It will hold cash and cash-like instruments as collateral.